CMES206 An Investigative Symposium on Key Lipid and Glucose Challenges of Practice in T2DM

Program: CMES Ancillary Events
Monday, June 17, 2013: 6:30 PM-9:30 PM
Yerba Buena Salon 7 (San Francisco Marriott Marquis)

Learning Objectives:

  • Develop strategies to align practice guidelines and consensus recommendations with current standards of care and to apply these appropriately for the care of patients with T2DM to optimize clinical outcomes
  • Apply key clinical concepts of dyslipidemia, including hypertriglyceridemia and elevated non-HDL-C in the in the management of patients with T2DM
  • Discuss the mechanisms of action and clinical data describing the safety and efficacy of available and emerging therapies including SGLT-2 inhibition therapies in patients with T2DM for the prevention of microvascular and/or macrovascular complications
  • Incorporate multifaceted, recommended approaches to attaining treatment goals including glycemic control, lipid management, and controlling other CV risk factors to avoid microvascular and/or macrovascular complications
This activity is supported by an independent educational grant from Amarin Pharma Inc. and Boehringer-Ingelheim Pharmaceuticals, Inc, which is made possible in part through collaboration with Eli Lilly and Company
7:00 PM
James R Gavin III, PHD, MD, Emory Univ Schl of Med, Fayetteville, GA
7:15 PM
Robert Harold Eckel, MD, Medicine - Division of Endocrinology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO
7:45 PM
Harold Edward Bays, MD, L-MARC Rsrch Cntr, Louisville, KY
8:15 PM
Lawrence Blonde, MD, FACP, Ochsner Medical Center, New Orleans, LA
8:45 PM
James R Gavin III, PHD, MD, Emory Univ Schl of Med, Fayetteville, GA
See more of: CMES Ancillary Events